peptibase
Hormonal

Pasireotide

Also known as: Signifor, Signifor LAR

FDA Approved
Share:

Key Facts: Pasireotide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Cushing's disease and acromegaly
Administration
Subcutaneous or intramuscular
Typical Dose
300-900 mcg twice daily
Frequency
Twice daily (SC) or monthly (LAR)
Duration
Long-term / chronic use
Also Known As
Signifor, Signifor LAR

Mechanism of Action

Pasireotide binds to somatostatin receptors 1, 2, 3, and 5 with high affinity. The SST5 binding is particularly important for suppressing ACTH secretion from corticotroph adenomas in Cushing's disease.

Research Summary

Only FDA-approved medical therapy for Cushing's disease. Studies show significant reduction in urinary free cortisol. Also approved for acromegaly when other somatostatin analogs fail.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

300-900 mcg twice daily

Range

300-900 mcg per dose

Frequency

Twice daily (SC) or monthly (LAR)

Somatostatin analog for Cushing's disease. Higher hyperglycemia risk than other somatostatins.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

Duration

Long-term / chronic use

Administration

Subcutaneous or intramuscular

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Hyperglycemia and diabetes (very common)
  • ●Diarrhea
  • ●Nausea
  • ●Gallstones
  • ●QT prolongation (serious)
  • ●Liver enzyme elevations
  • ●Adrenal insufficiency
  • ●FDA approved (Signifor)

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Frequently Asked Questions

What does Pasireotide do?

A somatostatin analog with broader receptor binding than octreotide. Specifically effective for Cushing's disease due to SST5 activity.

How does Pasireotide work?

Pasireotide binds to somatostatin receptors 1, 2, 3, and 5 with high affinity. The SST5 binding is particularly important for suppressing ACTH secretion from corticotroph adenomas in Cushing's disease.

Is Pasireotide FDA approved?

Yes, Pasireotide is FDA approved. FDA Approved - Cushing's disease and acromegaly

What are the side effects of Pasireotide?

Reported side effects include: Hyperglycemia and diabetes (very common), Diarrhea, Nausea, Gallstones, QT prolongation (serious). Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Pasireotide?

Community-reported common dose: 300-900 mcg twice daily (Twice daily (SC) or monthly (LAR)). Range: 300-900 mcg per dose. Administration: Subcutaneous or intramuscular. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Pasireotide or used in similar applications.

Oxytocin

FDA

A naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.

Hormonal

Gonadorelin

FDA

A synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.

Hormonal

Leuprolide

FDA

A GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

Hormonal

Desmopressin

FDA

A synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.

Hormonal

Octreotide

FDA

A synthetic somatostatin analog that inhibits multiple hormones. Used for acromegaly, carcinoid tumors, and various GI conditions.

Hormonal

Lanreotide

FDA

A long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.

Hormonal
How to Use PasireotidePasireotide AlternativesCompare with SimilarBrowse All Peptides

Want updates on Pasireotide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides